epoetin alfa




Concise Prescribing Info
Epoetin α
Anemia associated w/ chronic renal failure in patients on haemodialysis, peritoneal dialysis, non-dialysis adults. Anemia in cancer patients on chemotherapy; zidovudine-treated HIV-infected patients. Reduction of allogeneic blood transfusion in surgery patients.
Dosage/Direction for Use
Anemia associated w/ chronic renal failure Adult Starting dose: 50-100 u/kg 3 times wkly IV or SC. Anemia in cancer patient on chemotherapy Adult SC Recommended dose: 150-300 u/kg 3 times wkly or 40,000 u once a wk. Zidovudine-treated HIV-infected patient w/ serum erythropoietin level ≤500 mUnits/mL receiving zidovudine ≤4,200 mg/wk Recommended starting dose: 100 u/kg IV or SC 3 times wkly for 8 wk. Reduction of allogenic blood transfusion in surgery patient 300 u/kg/day SC for 10 days pre-op, on day of surgery & 4 days post-op. Alternate dose schedule: 600 u/kg SC once wkly (21, 14 & 7 days pre-op) then 4th dose on day of surgery. Premed w/ Fe supplement.
Hypersensitivity to mammalian cell-derived products, human albumin. Uncontrolled HTN. Patients who develop Ab mediated PRCA following erythropoietin treatment. Surgery patients who cannot receive adequate antithrombtic prophylaxis.
Special Precautions
Closely monitor Hb conc due to potential increased risk of thromboembolic events & fatal outcome when treated above range for indication of use. Patients w/ underlying haematologic disease (eg, haemolytic anemia, sickle cell anemia, thalasemia); known history of seizure disorder; porphyria. Regularly monitor platelet count during first 8 wk of therapy. Ab mediated pure red cell aplasia (PRCA) after mths to yrs of  SC therapy. Perform reticulocyte count in patients developing sudden lack of efficacy (decrease of 1-2 g/dL/mth in Hb conc) w/ increased need for transfusion. Discontinue immediately if PRCA is suspected. Hb levels in cancer patients should be measured on a regular basis until a stable level is achieved then periodically thereafter. Fe evaluation. BP should be adequately controlled before initiation of therapy. Chronic liver failure. Pregnancy & lactation.
Adverse Reactions
HTN, headache, arthralgia, nausea, edema, fatigue, diarrhea, vomiting, chest pain, skin reaction (administration site), asthenia, dizziness, clotted access, pyrexia, constipation, DVT.
Drug Interactions
Effect may be potentiated by simultaneous therapeutic administration of haematinic agents eg, ferrous sulphate when a deficiency state exist.
ATC Classification
B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Erykine inj 4,000 IU/mL
1's (Rp281,900/boks)
Erykine inj 2,000 IU/mL
1's (Rp153,570/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in